TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with Group 2 Pulmonary ...

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

"We also await data of the use of sotatercept in post-capillary pulmonary hypertension ... related to their elevated blood pressure in pulmonary circulation and weakening heart muscle.

Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge ...

One study indicated that EIPH-positive horses had higher hematocrit values, which may contribute to increased pulmonary capillary pressure, a factor in the development of EIPH[1]. Additionally ...

Alveolar Capillary Dysplasia (ACD ... leading to severe respiratory issues in newborns. Pulmonary Arterial Hypertension (PAH): A type of high blood pressure that affects the arteries in the ...

In the overall study population, TX45 achieved a 17.9% reduction in pulmonary capillary wedge pressure (“PCWP”), an endpoint known to correlate with exercise capacity, morbidity and mortality ...